Milestone Pharmaceuticals Inc.

https://lifesciadvisors.com

Milestone Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative cardiovascular medicines. The company's mission is to improve the lives of individuals with cardiovascular conditions by empowering them to self-manage their care. Headquartered in Montreal, Quebec, Canada, Milestone Pharmaceuticals focuses on creating treatment solutions that can be self-administered outside traditional emergency or healthcare settings.

The company's primary product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker. This product is approved for the acute treatment of paroxysmal supraventricular tachycardia (PSVT) in adults, offering the first self-administered treatment option for this condition. Milestone Pharmaceuticals is also advancing etripamil for other episodic cardiovascular conditions, including atrial fibrillation with rapid ventricular rate (AFib-RVR).

Milestone Pharmaceuticals achieved a significant milestone with the FDA approval of CARDAMYST™ (etripamil) nasal spray in December 2025, with the product becoming available in U.S. retail pharmacies in early 2026. In March 2026, Express Scripts added CARDAMYST™ to its commercial national formularies, expanding patient access. Led by President and CEO Joseph Oliveto, the company has transitioned from a development-stage biotechnology firm to a commercial-stage specialty pharmaceutical operator, emphasizing therapies that provide patients with an active role in managing their conditions.

Latest updates

Milestone Launches Registry to Bolster Real-World Evidence for CARDAMYST

Event summary

  • Milestone Pharmaceuticals initiated the RESET-PSVT registry, a Phase 4, multicenter, prospective, observational study.
  • The registry aims to enroll approximately 450 adult patients across 20 sites, starting by the end of 2026.
  • RESET-PSVT will evaluate CARDAMYST (etripamil) usage patterns and patient-reported outcomes in PSVT management.
  • The study is being led by the Duke Clinical Research Institute (DCRI).

The big picture

The launch of RESET-PSVT underscores the growing emphasis on real-world evidence (RWE) in pharmaceutical marketing and post-approval studies. This registry represents a strategic effort by Milestone to expand CARDAMYST’s clinical utility beyond controlled trials and address the increasing demand for data demonstrating value in routine clinical practice. The reliance on the DCRI, a leading research institution, lends credibility to the findings and could influence physician prescribing behavior.

What we're watching

Enrollment Pace
The speed of patient enrollment will be a key indicator of the registry’s overall success and the willingness of clinicians to participate, potentially impacting the timeline for data generation.
Data Integrity
The reliability of patient-reported outcomes and survey data will be crucial for generating actionable insights and influencing treatment guidelines, requiring robust data validation processes.
Commercial Impact
The registry’s findings could significantly influence CARDAMYST’s market adoption and reimbursement landscape, particularly if they demonstrate improved patient quality of life or reduced healthcare utilization.

Milestone to Present at Needham Conference Amid AFib Development

Event summary

  • Milestone Pharmaceuticals will present at the 25th Annual Needham Virtual Healthcare Conference, April 13-16, 2026.
  • A webcast of the presentation will be available April 13th at 3:45 PM EDT.
  • Milestone’s lead product, CARDAMYST™ (etripamil), is approved for PSVT and in development for AFib-RVR.
  • Investors interested in meeting with Milestone’s team should contact their Needham representative.

The big picture

Milestone’s presentation at Needham’s conference underscores the ongoing need for cardiovascular therapies, particularly those addressing atrial fibrillation. The company’s focus on etripamil, with its dual indication potential, positions it within a competitive market requiring strong execution and clinical data to differentiate. The conference provides a platform to manage expectations and potentially attract further investment as the company navigates the complexities of drug development and commercialization.

What we're watching

Development Progress
The conference presentation will likely detail progress in the development of etripamil for AFib-RVR, a significantly larger market opportunity than PSVT, and the success of that program will be crucial for Milestone’s long-term growth.
Investor Sentiment
Needham’s involvement suggests a focus on investor relations, and the conference will provide a gauge of current sentiment regarding Milestone’s pipeline and commercial strategy, particularly given the competitive landscape in cardiovascular therapies.
Commercial Execution
The company’s ability to effectively communicate its commercial strategy for CARDAMYST™ and its expansion plans will be critical in maintaining investor confidence and justifying its current valuation.

Express Scripts Formulary Inclusion Boosts Milestone's CARDAMYST Access

Event summary

  • Milestone Pharmaceuticals’ CARDAMYST (etripamil) nasal spray has been added to Express Scripts’ commercial national formularies, effective March 27, 2026.
  • CARDAMYST is the first FDA-approved nasal spray for self-administered conversion of acute symptomatic paroxysmal supraventricular tachycardia (PSVT).
  • The inclusion represents the first contracted formulary acceptance for CARDAMYST by a major payer.
  • CARDAMYST is indicated for adults experiencing acute symptomatic PSVT episodes, a condition affecting approximately 2 million people in the U.S.

The big picture

This formulary inclusion is a critical milestone for Milestone, marking the first major payer acceptance of CARDAMYST and significantly expanding patient access. The drug addresses a clear unmet need for a self-administered PSVT treatment, potentially reducing reliance on emergency room visits and invasive procedures. However, success hinges on Milestone’s ability to manage manufacturing costs and negotiate favorable reimbursement rates with other payers to ensure affordability and sustained market adoption.

What we're watching

Payer Adoption
The speed at which other major insurance providers adopt CARDAMYST will be a key indicator of the drug’s overall commercial success and Milestone’s negotiating leverage.
Market Penetration
How effectively Milestone can drive awareness and utilization of CARDAMYST among cardiologists and patients will determine if the drug can capture a meaningful share of the PSVT treatment market.
Clinical Expansion
The progress of etripamil's Phase 2 pediatric and Phase 3 AFib-RVR trials will influence Milestone’s long-term pipeline value and potential for broader market applications.

Milestone's Cardamyst Launch Gains Traction, Funding Boosts Runway

Event summary

  • Milestone Pharmaceuticals received FDA approval for CARDAMYST (etripamil) nasal spray in December 2025, marking the first new treatment option for PSVT in 30 years.
  • The company reported $1.5 million in revenue for the fourth quarter and full year 2025, primarily from a milestone payment related to the FDA approval.
  • Milestone secured $75 million from RTW Royalty I DAC and $19 million from ATM sales and warrant exercises, providing a pro forma cash runway into late 2027.
  • The company deployed its national sales force within eight weeks of approval and reports positive initial engagement from healthcare providers and payers.

The big picture

Milestone's CARDAMYST represents a rare opportunity in a relatively stagnant cardiovascular treatment space, addressing a significant unmet need for a rapid-acting, self-administered PSVT therapy. The company's ability to execute on its commercial launch plan and secure favorable reimbursement will be crucial for long-term success. The recent financing provides a buffer, but the company's burn rate and ability to generate sustainable revenue will be key factors for investors to monitor.

What we're watching

Market Adoption
The pace at which CARDAMYST gains market share will be critical, as initial prescription data will be a key indicator of physician and patient acceptance, and payer coverage decisions will significantly impact revenue generation.
Regulatory Risk
The EMA’s decision on etripamil’s marketing authorization application, expected in the first half of 2027, will determine the product’s commercial potential in Europe and could impact investor sentiment.
AFib Expansion
Milestone’s progress in the Phase 3 program for AFib-RVR will be closely watched, as success in this indication could significantly expand the product’s addressable market and long-term revenue potential.

Milestone Data Highlights Minimal Blood Pressure Impact of Etripamil

Event summary

  • Milestone Pharmaceuticals will present data at the 2026 American College of Cardiology (ACC.26) conference demonstrating minimal blood pressure effects from etripamil (CARDAMYST™) during Phase 3 trials for PSVT.
  • The data, presented March 29, 2026, showed a mean systolic BP change of 1.8 mmHg (SD 11.2) with a single dose and 0.0 mmHg (SD 12.0) with repeat doses.
  • Adverse events of hypotension and syncope within 24 hours were low (0.4% and 0.2%, respectively) across 1,610 patients.
  • CARDAMYST™ was FDA-approved in December 2025 as the first self-administered treatment for symptomatic PSVT.

The big picture

Milestone's CARDAMYST™ represents a shift towards patient-centric care in cardiovascular medicine, offering a self-administered option for PSVT management. The data presented aims to address concerns about potential hypotension, a common side effect of CCBs, and bolster confidence in the product's safety profile. Success hinges on demonstrating real-world efficacy and navigating regulatory hurdles in key markets.

What we're watching

Clinical Adoption
The ACC presentation and subsequent physician feedback will be critical in determining the rate of adoption of CARDAMYST™ within the cardiology community, given the novelty of a self-administered nasal spray.
Regulatory Risk
The EMA’s assessment of Milestone’s Marketing Authorization Application (MMA) for etripamil, and any potential requests for additional clinical data, will significantly impact the product’s European market potential.
Commercial Execution
Milestone’s ability to effectively educate patients and physicians on the proper use and benefits of CARDAMYST™ will be key to achieving sustainable revenue growth and justifying the company’s valuation.

Milestone Executives to Present at TD Cowen Healthcare Conference

Event summary

  • Milestone Pharmaceuticals executives Amit Hasija (CFO) and Lorenz Muller (CCO) will present at the TD Cowen 46th Annual Health Care Conference.
  • The conference takes place March 2-4, 2026, in Boston.
  • A webcast of the presentation will be available on March 3rd at 9:10 AM EST.
  • Investors interested in meeting with Milestone’s team should contact their TD Cowen representative.

The big picture

Milestone's participation in a major healthcare conference underscores its ongoing efforts to raise investor awareness and potentially secure additional funding. The company's focus on cardiovascular medicines, particularly etripamil’s expansion beyond PSVT, positions it within a competitive but growing market segment. The conference provides a platform to articulate the company’s strategy and address investor questions regarding its commercialization efforts and pipeline development.

What we're watching

Investor Relations
The presentation and availability of a webcast suggest Milestone is actively engaging with investors, potentially to address concerns or highlight progress on their AFib-RVR development program.
Commercial Execution
The presence of the Chief Commercial Officer indicates a focus on CARDAMYST’s market penetration and future growth, which will be critical for Milestone’s financial performance.
Pipeline Progress
The conference presentation will likely provide updates on the progress of etripamil’s development for AFib-RVR, a significantly larger market opportunity than its current PSVT indication.

Milestone Bolsters Legal Team Amidst Cardamyst Commercialization

Event summary

  • Milestone Pharmaceuticals appointed David Sandoval as General Counsel and Chief Compliance Officer, effective immediately.
  • Sandoval’s appointment coincides with the launch of CARDAMYST™ (etripamil) nasal spray, approved by the FDA on December 12, 2025.
  • Sandoval brings over 15 years of experience in legal and compliance within the life sciences sector, particularly in late-stage development and commercialization.
  • Prior roles include Senior Vice President, General Counsel, Corporate Compliance Officer and Corporate Secretary at MaxCyte, Inc.

The big picture

The appointment of a seasoned legal and compliance officer like Sandoval signals Milestone's commitment to navigating the complexities of commercializing a novel pharmaceutical product in a highly regulated environment. This move is particularly important given the increasing emphasis on corporate governance and SEC compliance within the biopharmaceutical sector, where regulatory missteps can carry significant financial and reputational consequences. The timing aligns with the critical phase of CARDAMYST’s market entry and the need to establish a robust legal framework for long-term growth.

What we're watching

Regulatory Headwinds
The effectiveness of Sandoval’s compliance programs will be crucial given CARDAMYST’s novel delivery method and potential for scrutiny regarding patient self-administration.
Execution Risk
Milestone’s ability to scale operations and build infrastructure to support CARDAMYST’s commercialization will be heavily influenced by Sandoval’s legal and compliance expertise.
Litigation Exposure
Given the product's safety profile and potential for adverse events, the frequency and severity of any future litigation will be a key indicator of long-term value.

Milestone Launches First-in-Class PSVT Treatment, Faces Coverage Hurdles

Event summary

  • Milestone Pharmaceuticals launched CARDAMYST™ (etripamil) nasal spray, the first FDA-approved self-administered treatment for paroxysmal supraventricular tachycardia (PSVT), on January 26, 2026.
  • The FDA approved CARDAMYST on December 12, 2025, marking the first approval in over 30 years for this condition.
  • Milestone plans to deploy a national sales force in mid-February 2026 and expects a $25 copay cap for eligible insured patients.
  • The company is implementing a patient assistance program to support benefits verification and reimbursement.

The big picture

CARDAMYST addresses a significant unmet need in the treatment of PSVT, a condition often managed through costly and inconvenient emergency room visits or invasive procedures. The lack of recent innovation in this space creates an opportunity for Milestone, but the company faces the common challenge of securing payer coverage for novel therapies. The $25 copay cap suggests an aggressive strategy to drive initial adoption, but long-term profitability depends on broader insurance acceptance.

What we're watching

Coverage Dynamics
The success of CARDAMYST hinges on securing broad formulary coverage and favorable reimbursement rates, which will dictate patient access and revenue generation.
Market Penetration
The effectiveness of Milestone’s national sales force and patient assistance program will determine the speed and extent of market penetration within the estimated 2 million PSVT sufferers in the U.S.
Pipeline Risk
Milestone’s future growth is tied to the progress of etripamil in Phase 2 pediatric PSVT and Phase 3 AFib-RVR trials, introducing pipeline risk if these programs encounter setbacks.
CID: 541